

CURRICULUM VITAE

NAME: Angela Yen Moore, MD

DATE: 03/05/09

PRESENT POSITION AND ADDRESS:

Dermatopathologist 2008-present

ACD Pathology
711 East Lamar Blvd.
Arlington, TX 76011
Ph: 817-795-7546
Fax: 817-226-7546

Dermatologist and Dermatopathologist 1998-present

Arlington Center for Dermatology
711 East Lamar Blvd, Suite 200
Arlington, TX 76011
Ph: 817-795-7546
Fax: 817-226-7546
Email: acderm@acderm.com
Website: www.acderm.com

Principal Investigator 1997- present

Arlington Research Center, Inc
711 East Lamar Blvd, Suite 200
Arlington, TX 76011
Ph: 682-365-3602
Fax: 817-226-7546

Clinical Assistant Professor of Dermatology 2000-present

Baylor University Medical Center
3500 Gaston Ave.
Dallas, TX 75246
Ph: 214-820-2468
Fax: 214-820-4538

Clinical Assistant Professor of Dermatology 1997-present

University of Texas Medical Branch at Galveston
301 University Blvd. Route G-83
Galveston, Texas 77550
Ph: 409-772-1911
Fax: 409-772-1943

Adjunct Assistant Clinical Professor 2000-present

The University of Texas at Arlington School of Nursing
Box 19407
411 S Nedderman Dr
Arlington, Texas 76019

Ph: 817-272-2776
Fax: 817-272-5006

PREVIOUS POSITIONS:

Clinical Assistant Professor of Dermatology	1998-2005
The University of Texas Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75235-9069 Ph: 214-648-2274 Fax: 214-648-0280 Email: acderm@acderm.com	
Dermatologist	June, 1998- July, 1999
Mullanax Dermatology Associates 715 North Fielder Arlington, Texas 76012 Ph: 817-261-1626 Fax: 817-275-0441	
Dermatopathologist	August, 1998- Sept, 1999
Cockerell and Associates 2330 Butler Street, Suite 115 Dallas, Texas 75235 Ph: 214-638-2222 Fax: 214-630-5210	
Dermatologist and Dermatopathologist	September, 1998- Sept, 1999
Department of Veterans Affairs, North Texas Health Care System Dallas Veterans Affairs Medical Center 4500 South Lancaster Road Dallas, Texas 75216 Ph: 214-372-7032	
Dermatologist	July, 1999- Dec, 2000
Arlington Dermatology Clinic 801 Road to Six Flags West, Suite 139 Arlington, Texas 76012 Ph: 265-1356	

EDUCATION:

1985-88 University of Texas, Austin, Texas, B.A. in Biology with Special Honors
(Summa Cum Laude)

1988-92 Baylor College of Medicine, Houston, Texas, M.D.

1992-93 University of Texas Medical Branch, Galveston, Texas, Internal Medicine
Internship

- 1993-96 University of Texas Medical Branch, Galveston, Texas, Dermatology Residency
- 1996-97 University of Texas Medical Branch, Galveston, Texas, Dermatopathology Fellowship

LICENSURE/ BOARD CERTIFICATION:

Texas State Board of Medical Examiners (expires 5/2009)
Diplomate of the American Board of Dermatology (since 1996, expires 2117)
American Board of Dermatopathology (1997)

MEMBERSHIPS IN SCIENTIFIC SOCIETIES:

American Medical Association (1988- present)
Texas Medical Association (1988- present)
American Academy of Dermatology (1993- present)
Society of Investigative Dermatology (1993- present)
Southern Medical Association (1993- present)
Dermatology Foundation (1993- present)
Houston Dermatological Society (1993- present)
Women's Dermatologic Society (1996- present)
Houston Society of Clinical Pathologists (1996- present)
American Board of Medical Specialties (1997-present)
American Society of Dermatopathology (1998-present)
American Acne and Rosacea Society (2009-present)

LEADERSHIP:

Director, Texas Dermatology Society Spring Meeting (2010)
Appointed Member of the Program Committee of Texas Dermatological Society (2008-2011)
Member of the Editorial Board of the Journal of the American Academy of Dermatology (JAAD) (2008-2013)
Secretary-Treasurer, Fort Worth Dermatological Society (2008-2010)
Vice President, Fort Worth Dermatological Society (2005-2007)
President, Arlington Medical Society (2003-04)
Committee member on Project Access to organize healthcare for indigent patients in Tarrant County (2003-04)
President-Elect, Arlington Medical Society (2002-2003)
Secretary-Treasurer, Arlington Medical Society (2001-2002)
Resident Member, American Academy of Dermatology Melanoma/Skin Cancer Screening Programs Task Force, (1996-97)
Delegate, American Medical Association Resident Physician Section (1996-97)
Resident Representative, Texas Medical Association Preventive Medicine Task Force (1996-97)
Resident Representative (Alt), Texas Medical Association Public Health Council (1996-97)
Resident Representative, Texas Medical Association Scientific Affairs Council (1995-97)
Resident Representative, Texas Medical Association Environment Committee (1995-96)
Texas Medical Association Resident Physician Section Council Member (1995-97)

Chairman, University of Texas at Austin Career Contacts Committee (1987-1988)
Student Advisor, University of Texas at Austin Blanton Dormitory, 5th floor (1986-1988)
Natural Sciences Representative, University of Texas at Austin Student's Association Student Senate (1986-1987)
Chair and Vice-chair, University of Texas at Austin Student's Association Consumer Affairs Committee (1986-1987, 1985-1986)
President, American Field Service, (1984-85)
President, German Club, (1984-85)
President, Math & Science Team, (1984-85)

SERVICE:

Volunteer at annual Tarrant County skin cancer screenings (1998-present)
Medical missionary trip to Ecuador (2008)
Medical missionary trip to East Asia (2007)
Medical missionary trip to China (2006)
Volunteer at the Medical Center of Arlington skin cancer screening (2006)
Volunteer at Texas Motor Speedway skin cancer screening (2006)
Volunteer at Mission Arlington for dermatology care (2005-present)
Provide skin care information at local health fairs (2005-present)
Volunteer at Colonial and Byron Nelson golf tournaments skin cancer screenings (2005)
Medical missionary trip to China (1999)
Medical missionary trip to Bangkok, Thailand (1998)
Medical missionary trip to Juarez, Mexico (1997)
Medical missionary trip to Matamoros, Mexico (1997)
Judge for Galveston Ball High School Science Fair (1997)
Judge for National Student Research Forum (1997)
Pianist in the St. Vincent's Clinic Benefit (1997)
Medical missionary trip to Xian, China (1995)

TEACHING:

Dermatopathology weekly "Clinicopathological Correlation" Conference at The University of Texas Southwestern at Dallas, 1998-present
Dermatopathology weekly "Unknowns" conference and "Clinicopathological Correlation" Conference at The University of Texas Southwestern at Dallas, Veterans' Affairs Hospital, 1998-99
Dermatopathology weekly "Unknowns" conference and textbook conference at University of Texas Medical Branch at Galveston, 1996-98
Chief Resident of Dermatology, 1995-96
Weekly lectures for medical students and residents, 1995-96
Oral presentation on "Diagnostic Dilemma of Lymphoma vs. Histiocytic Necrotizing Lymphadenitis" at Pediatric Grand Rounds, University of Texas Medical Branch at Galveston, March, 1995.
Oral presentation on "Mucoepidermoid carcinoma" at the Otolaryngology Tumor Board Conference, University of Texas Medical Branch at Galveston, March, 1995.
Oral presentation on "Classification and Therapy of Hansen's Disease" at Infectious Disease Grand Rounds, University of Texas Medical Branch at Galveston, March, 1995.

Oral presentation on "Leukemia Cutis" at Pediatric Grand Rounds, University of Texas Medical Branch at Galveston, May, 1994.

UTMB COMMITTEE RESPONSIBILITIES:

President, University of Texas Medical Branch at Galveston Housestaff Officers Association, 1995-96

University of Texas Medical Branch at Galveston Graduate Medical Education Advisory Committee, 1995-present

University of Texas Medical Branch at Galveston Trauma, Infection & Repair Task Force, 1995-97

University of Texas Medical Branch at Galveston Internal Review Committee of the Institutional Residency Program, 1996

University of Texas Medical Branch at Galveston Planning committee, 12th Floor Sleep Room Project, 1996-97

University of Texas Medical Branch at Galveston Department of Family Medicine Internal Review Committee, 1996

Residency Selection and Evaluation Committee, Department of Dermatology, 1993-present

RESEARCH GRANTS/FELLOWSHIPS (National, International):

Dermatology Foundation Clinical Career Development Award, "Molecular predictors of metastasis and survival in intermediate-thickness melanomas", 1999-2002.

Dermatology Foundation Research grant, "Molecular predictors of metastasis and survival in intermediate-thickness melanomas", 1999-2000.

The Skin Cancer Foundation Frederic E. Mohs grant, "Predictors of metastasis and survival in intermediate-thickness melanomas", 1999-2000.

World Congress Fund Travel Scholarship to the 1998 International Investigative Dermatology Meeting in Cologne, Germany ("Expression of Human Herpesvirus 8 Cellular Homologue Genes in Kaposi's Sarcoma"), 1998.

World Congress Fund Travel Scholarship to the 19th World Congress of Dermatology in Sydney, Australia ("Human Herpesvirus 8 (HHV-8) in Cutaneous Malignant and Autoimmune Lesions: Sequence Variability of HHV-8 DNA in Kaposi's Sarcoma, Squamous Carcinomas, and Pemphigus"), 1997.

Southern Medical Association Research Grant, "Prevalence and Potential Role of HHV-8 in Kaposi's Sarcoma and Autoimmune Disorders," 1996-97.

Women's Dermatologic Society Grant for Mentorship, Melbourne, Australia (with Dr. Robin Marks), 1996

Society of Investigative Dermatology Albert M. Kligman Fellowship ("Prevalence of Human Herpesvirus 8 DNA in Kaposi's Sarcoma, Carcinomas, and Post-transplant Squamous

Lesions”), 1996.

Invited Guest Clinician at Xian Medical School, Xian, China, 1995.

HONORS/AWARDS:

Dermatology

Texas Super Doctors – Elected by peers and recognized in Texas Monthly, December 2007

Texas Super Doctors – Elected by peers and recognized in Texas Monthly, December 2006

Dallas Fort Worth Dermatologic Society 2006 Practicing Physicians “Case of the Year” award, 2006, Dallas, Texas.

Texas Super Doctors – Elected by peers and recognized in Texas Monthly, December 2005.

Texas Super Doctors – Elected by peers and recognized in Texas Monthly, December 2004.

Outstanding Poster Award for “Methylation Profiles of Tumor Suppressor Genes in Basal Cell and Squamous Cell Carcinomas” at the North Texas Chapter of the American College of Surgeons Meeting, Dallas, Texas, February, 2003.

Outstanding Poster Award for “Loss of Heterozygosity at 6q22-23.3 in Congenital Nevi, Acquired Nevi, and Cutaneous Melanoma after Laser Capture Microdissection” Presentation at the North Texas Chapter, American College of Surgeons Meeting, Dallas, Texas, February, 2002.

Skin Disease-Related Research Core Center Grant, 2002-2003.

Dallas Fort Worth Dermatologic Society 1999 Practicing Physicians “Case of the Year” award, 1999, Dallas, Texas.

Dermatology Foundation Clinical Career Development Award, 1999-2002.

Skin Cancer Foundation Grant, 1999-2000.

Dermatology Foundation Research Grant, 1999-2000.

American Academy of Dermatology 1999 Award for Young Investigators in Dermatology, March 1999, New Orleans, Louisiana.

Young Investigators’ Award Honorable Mention from the American Society for Dermatologic Surgery, February, 1997

UTMB Department of Dermatology Research Award at the National Student Research Forum, April, 1996, Galveston, Texas

American Academy of Family Physician Research Award at the National Student Research Forum, April, 1995, Galveston, Texas

Roche Overall Award for Clinical Research, Resident/Intern Division at the National Student Research Forum, April, 1995, Galveston, Texas

Roche Overall Award for Basic Science Research, Resident/Intern Division at the National Student Research Forum, April, 1994, Galveston, Texas

J. Lewis Pipkin Research Award (Department of Dermatology) at the National Student Research Forum, April, 1994, Galveston, Texas

Galveston Symphony Orchestra, violinist, 1995

Undergraduate

Phi Beta Kappa, 1988

Second degree Black Belt in Tae Kwon Do, 1988

Friar Society (based on significant contribution in research and service to UT), 1988

Cactus Goodfellow Award for Scholarship, Leadership, and Service, 1988
Outstanding College Students of America, Fall 1987
Who's Who Among Students in American Universities and Colleges, Spring 1987
Cactus Outstanding Student Award for Scholarship, Leadership, and Service, Spring 1987
President's Endowed Scholar, Spring 1987
Mortar Board Honorary Service Organization, Spring 1987
Omicron Delta Kappa for Leadership Scholarship, Spring 1987
Phi Kappa Phi Honor Society, 1986
Golden Key National Honor Society, Fall 1986
Neel A. Harrington Scholarship (to one junior student annually), 1986-1987
Margaret C. Berry Scholarship (to one female sophomore annually), Spring 1986
Jostens' Scholarship for Scholarship and Leadership, 1985-1988
Textron National Merit Scholarship, 1985-1988
Independent Order of Foresters Award for Scholarship & Leadership, 1985-1988
Texas Achievement Award, 1985-1988
Texas Excellence Award (Lowell Lebermann 1985 Texas Scholar), 1985-1988
Outstanding Orchestra Student Award, Member of the All-State Symphonic Orchestra, 1985
National Merit Scholar, 1985
Valedictorian (Graduating Class of 550) at Arlington High School, June 1985

ADVISORY BOARD

Abbott, Amgen, Astella, Biogen Idec, Centacor, Connectics, Dermik, Ferndale, Galderma, GlaxoSmithKline, Medicis, 3M, Novartis, Stiefel Regional and Warner Lambert

CURRENT SPEAKER'S BUREAU INVOLVEMENT (Roundtable and Lecture):

Abbott-Psoriasis and Psoriatic Arthritis, Use of Biologics for Psoriasis and Psoriatic Arthritis, Pearls on Private Practice, 2006 to present
Amgen- Psoriasis and Psoriatic Arthritis, Intervention in Psoriatic Arthritis and Psoriasis, 2004, 2005
Astellas/Fujisawa – The Many Faces of Lupus, Dermatology Pearls, Private Practice Dermatology Pearls, 2003 to present
Biogen- Psoriasis in the Era of Biologics, Pearls on Private Practice Dermatology, Electronic Medical Records and Modern Day Technology in the treatment of Psoriasis, 2003-2005
Collagenex - Topics include Rosacea, Pearls and Potpourri of Cases, 2006 to present
Connetics - Topics include Atopic dermatitis, Seborrheic dermatitis, Contact dermatitis, Dyshidrotic eczema, and Psoriasis in the Era of Biologics, Combination Treatment for Psoriasis, , 2001 to present
Dermik – Dermatology Pearls, Potpourri of Dermatology Cases from Around the World, Electronic Medical Records, Benzaclin, Carac, 2003 to present
Ferndale Laboratories- Use of Immunomodulators and Steroids in Inflammatory Disorders, 2003 to present
Galderma- Pearls on Private Practice, Topical Steroids in Novel Vehicles, Clobex Shampoo, Metrogel, Differin, Triluma, Update on the M.O.R.E. Trial, 2006 to present
Glaxo Smith Kline- Topics include Herpesviruses 1-8, Cutaneous Manifestations of Viral Diseases, 2002-03
Healthpoint- Inflammatory Skin Diseases 2003-2004

3M- Topics include Human Papillomaviruses, Cutaneous carcinomas, Cutaneous Manifestations of Viral Diseases, Antiviral therapies, Herpesviruses 1-8, Dermatology from Around the World, Pearls from the American Academy of Dermatology Meeting, Potpourri of Dermatology Cases, Skin Cancer Update, Pearls on Skin Cancer Treatment, 2001 to present
Novartis- Topics include Herpesviruses and Antiviral therapies, Atopic Dermatitis, Advanced Diagnosis and Treatment of Inflammatory Skin Disorders, Update on Treatment of Inflammatory Skin Disorders, Therapy of Inflammatory Diseases, Scaly Rashes, 2001 to present
Warner Lambert- Dermatology Cases from Around the World, 2003, Taclonex, 2006 to present

FUNDED RESEARCH PROJECTS:

Principal Investigator: Moore A., Protocol Number GLI.04SPRUS10120: “A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea” Galderma R&D, Inc., March 2009- Present.

Principal Investigator: Moore A., Protocol Number M10-467: “A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis Suppurativa” Abbott Laboratories, March 2009- Present.

Principal Investigator: Moore A., Protocol Number P10-023: “A 10 Year, Post Marketing, Observational, Registry of HUMIRA® (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis.” Abbott Laboratories, March 2009- Present.

Principal Investigator: Moore A., Protocol W0261-301: “A Phase 3 Multicenter, Randomized, Double-Blind, Active and Vehicle-Controlled Study of the Safety and Efficacy of Duac Low-Dose Gel Versus Clindamycin Gel Versus Benzoyl Peroxide Gel Versus Vehicle Gel in Subjects with Acne Vulgaris.” Stiefel Laboratories, Inc., October 2008 – Present.

Principal Investigator: Moore A., Protocol Number DPSI-IDP-107-P2-01: “A Phase 2B, Multi-Center, Double-Blind, Randomized, Dose-ranging Clinical Study to Evaluate IDP-107 in the Treatment of Moderate to Severe Acne Vulgaris with Nodular Involvement.” Dow Pharmaceuticals, September 2008- Present.

Principal Investigator: Moore A., Protocol Number C0168Z04: “A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE®) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to Etanercept (ENBREL®).” September 2008- Present.

Principal Investigator: Moore A., Protocol Number C0168Z03: “A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics.” May 2008- Present.

Principal Investigator: Moore A., Protocol U0275-01: “A Phase 4, Open-Label Study to Assess the Long-Term Safety of Extina (ketoconazole) Foam, 2%, in the Treatment of Seborrheic Dermatitis.” Stiefel Laboratories, Inc., June 2008 – Present.

Principal Investigator: Moore A., Protocol 70744001: “A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of Adapalene Cream 0.1% (Glenmark Pharmaceutical Ltd.) Compared to Differin® (adapalene 0.1%) Topical Cream (Galderma Laboratories) in Patients with Acne Vulgaris.” Novum , May 2008 – Present.

Principal Investigator: Moore A., Protocol RD.03.SPR.29075: “Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel versus Adapalene, 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel as a 6-Month Maintenance Treatment.” Galderma R&D, Inc., May 2008 – Present.

Principal Investigator: Moore A., Protocol RD.03.SPR.29074: “Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated with Doxycycline Hyclate 100mg Tablets versus Adapalene lotion, 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel Associated with Doxycycline Hyclate 100mg Tablets in the Treatment of Severe Acne Vulgaris.” Galderma R&D, Inc., May 2008 – Present.

Principal Investigator: Moore A., Protocol C0168Z03: “A Multicenter, Open Registry of Patients with Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics.” Centocor, Inc., April 2008 – Present.

Principal Investigator: Moore A., Protocol RD.06.SPR.18113: “A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared with Vehicle Lotion in Subjects with Acne Vulgaris.” Galderma R&D, Inc., February 2008 – Present.

Principal Investigator: Moore A., Protocol EPB348-0201: “A randomized, double-blind, active-controlled, multi-center, parallel-group dose-ranging study assessing the safety and efficacy of EPB-348 versus valacyclovir among immunocompetent patients with an acute episode of herpes zoster.” Epiphany Biosciences, December 2007 – Present.

Principal Investigator: Moore A., Protocol M10-016: “A Phase 3, Multicenter, Open-Label Extension Study Designed To Describe Safety, Tolerability, and Efficacy of Long-Term Administration of the Human Monoclonal Antibody Against IL-12 In Subjects with Moderate to Severe Chronic Plaque Psoriasis.” Abbott/Paragon Biomedical, May 2008 – Present.

Principal Investigator: Moore A., Protocol M06-890: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis.” Abbott/Paragon Biomedical, December 2007 – Present.

Principal Investigator: Moore A., Protocol 70716202: “A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of Adapalene Gel 0.1% (PLIVA Research & Development Ltd.) Compared to Differin (adapalene 0.1%) Topical Gel (Galderma Laboratories in Patients with Acne Vulgaris” Novum , June 2007 – Present.

Principal Investigator: Moore A., Protocol 15L-CL-101: “A Phase II Dose Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes.” Astellas , March 2007 – Present.

Principal Investigator: Moore A., Protocol COL101-ROSE-401: “A Multi-Center, Randomized, Double-Blind, Active-Control Clinical Trial to determine the Effects of Doxycycline Monohydrate Modified-Release Capsules, 40 mg (COL-101 Administered Once Daily in Conjunction with MetroGel (metronidazole topical gel, 1%) versus Doxycycline Hyclate Immediate-Release Capsules, 100 mg Administered Once Daily in Conjunction with MetroGel (metronidazole topical gel, 1%) in Patients with Moderate to Severe Rosacea.” Collagenex , February 2007 - Present

Principal Investigator: Moore A., “TAZ0601: Comparative Tolerability and Efficacy of Tazorac 0.1% and Retin-A Micro 0.04% in the Treatment of Mild to Moderate Facial Acne Vulgaris.” Allergan, Inc, January 2007-Present

Principal Investigator: Moore A., “Protocol RD.06.SPR.18088: A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Demonstrate The Efficacy And Safety Of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% And Topical Gel Vehicle In Subjects With Acne Vulgaris.” Galderma, January 2007-Present

Principal Investigator: Moore, A., “Protocol 20040210: Observational Post-Marketing Safety Surveillance Registry of Enbrel (etanercept) for the Treatment of Psoriasis.” Amgen Inc. May 2006-Present

Principal Investigator: Moore, A., “Protocol GLI.04.SPR.US10 029: A Phase IV, Open-Label, Multicenter, Community-based, 4-Week Trial Assessing Efficacy, Tolerance to Treatment, and Subject Satisfaction With Clobex (clobetasol propionate) Spray, 0.05% When Used as Monotherapy or as Add-on Therapy to Existing Systemic or Topical Antipsoriatic Agents for the Treatment of Moderate to Severe Plaque Psoriasis.” Galderma Laboratories, L.P., January 2006-April 2006

Principal Investigator: Moore, A., A Clinical Evaluation of Tazorac (tazarotene) Cream 0.1% indicated for the topical treatment of patients with acne vulgaris, who do not want to or are unable to participate in the IPLEDGE Program. Allergan, July 2006-October 2006

Principal Investigator: Moore, A., “Protocol BPI-06-001: A Prospective Double-Arm, Multicenter, Open label Phase IV Evaluation of the safety and efficacy of the use of Solaraze Gel in the treatment of AK lesions post cryosurgery.” Doak Dermatologics., April 2006-October 2006

Principal Investigator: Moore A., “Protocol #20040171: A Multicenter, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL in Combination with Narrowband UV-B Phototherapy for the Treatment of Psoriasis,” Omnicare/Amgen, September, 2005

Principal Investigator: Moore A., “Protocol ACD3101g, Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in patient with Moderate to Severe Plaque Psoriasis (RESPONSE),” Genentech, July 2005

Principal Investigator: Moore A., “Protocol # 04-0-207, A Phase 3, Long –Term, Open Label Study to Evaluate the Safety of Twice Daily 0.1% Tacrolimus Cream in the Treatment of Psoriasis.” Astellas Pharma US, September 2005 – August 2006.

Principal Investigator: Moore A. “Protocol 1520-IMIQ-19 Open-label Safety and Pharmacokinetic Study of Aldara 5% Cream for the Treatment of Contiguous and Non-contiguous Actinic Keratosis.” 3M Pharmaceuticals. June, 2005 – May, 2007

Principal Investigator: Moore A. “Protocol FHI 03-0-161/FG-506-06-37, A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis - APPLES” Astellas, A 10-year study to start in October, 2005.

Principal Investigator: Moore A. “Protocol 20050111: An Open-label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects with Plaque Psoriasis.” Amgen, July 2005 – Jul., 2007

Principal investigator: Moore A. “Protocol 20030211: Placebo-controlled Multicenter Study with Etanercept to Determine Safety and Efficacy in Pediatric Subjects with Plaque Psoriasis.” Amgen. Jan, 2005- 2006.

Principal investigator: Moore A. “Protocol CSFO327 2301, A randomized, investigator blinded, active-controlled, parallel-group study to compare the efficacy and safety of 6-week treatment with terbinafine new pediatric formulation versus 6-week treatment with griseofulvin pediatric suspension in children with Tinea capitis.” Novartis Pharmaceuticals, Feb. 2005-2006

Principal investigator: Moore A. “Protocol 03-0-166: A Phase 3, Randomized, Double-Blind Study Comparing Twice Daily Tacrolimus Cream 0.03% Versus Cream Vehicle in the Treatment Of Atopic Dermatitis In Pediatric Subjects.” Fujisawa Healthcare, Inc., Aug. 2004-Nov., 2004.

Principal investigator: Moore A. “Protocol 1502-IMIQ: Phase 3b, Open-labeled Efficacy and Safety Study of Imiquimod 5% Topical Cream in the Treatment of Actinic Keratosis.” 3M, April, 2004- present.

Principal investigator: Moore A. “Community Based Trial of Metrogel and the Treatment of Rosacea: CLEAR Study. Protocol GL1-04-SPR-0204001” Galaderma, April, 2004- Oct. 2004.

Principal investigator: Moore A. “Amgen Protocol 200030190-EASE Study: A Multicenter, Open-labeled, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in

the Treatment of Subjects with Psoriasis.” Amgen, 2004-2005.

Principal investigator: Moore A. “A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when ASM981 (pimecrolimus) cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in adults 18 years of age and older.” Novartis. Dec, 2003-2004.

Principal investigator: Moore A. “ACD2782g: A Phase IIIB, Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab In Adults With Moderate to Severe Plaque Psoriasis Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned from Systemic Therapies.” Genentech. 2003-2004.

Principal investigator: Moore A. “Assessment and Tracking of Long-Term Alefacept (LFA-3/IgG1 Fusion Protein) Safety (ATLAS).” Biogen. 2003

Principal investigator: Moore A. “Amgen Protocol 20030106: Experience Diagnosing, Understanding Care, and Treatment with ENBREL in Psoriatic Arthritis,” 2003-2004.

Principal investigator: Moore A. “Prospective Investigation Gauging Melasma Reduction with a New Treatment: A Multicenter, Community-Based Trial to Assess the Efficacy and Safety of Tri-Luma™ Cream in the of Facial Melasma using fluocinolone acetone (0.01%), hydroquinone (4%), tretinoin (0.05%)”. Galaderma. 2002-2003

Principal investigator: Moore A. “Aberrant Promotor Methylation Profiles of Sporadic Cutaneous Carcinomas,” 2001-2003.

Principal investigator: Moore A. “Efficacy of Topical Ciclopirox for Tinea Pedis,” 2000-2001.

Principal investigator: Moore A. “Loss of Heterozygosity Analysis of Cutaneous Melanoma Cells Acquired by Laser Capture Microdissection,” 1999-2002.

Principal investigator: Moore A. “Safety and Efficacy of Sequential Therapy with Topical Calcipotriene ointment 0.005% and Halobetasol Ointment 0.05% in Treatment of Plaque-Stage Psoriasis,” 1999-2001.

Principal investigator: Moore A. “Safety and Efficacy of Topical Tazarotene Gel 0.1% in Facial Acne Vulgaris,” 1999-2000.

Principal investigator: Dermatology Foundation Clinical Career Development Award: Moore A. “Predictors of Metastasis and Survival in Intermediate-Thickness Melanomas,” 1999-2002.

Principal investigator: Skin Cancer Foundation Grant: Moore A. “Predictors of Metastasis and Survival in Intermediate-Thickness Melanomas,” 1999-2000.

Principal investigator: Dermatology Foundation Research Grant: **Moore A.** “Predictors of Metastasis and Survival in Intermediate-Thickness Melanomas,” 1999-2000.

Principal investigator: **Yen A,** Scheel M, Chen SW. “A Double-Blind, Placebo Controlled, Randomized Study of Venlafaxine Extended Release Capsules for the Treatment of Chronic Pain Associated with Post-Herpetic Neuralgia,” 1997-2000.

Co-investigator: Skin Disease-Related Research Core Center Grant: Gazdar AF, **Moore A.** “Methylation Profiles of Tumor Suppressor Genes in Skin Cancers and in Sun Damaged Skin,” 2002-2003.

Co-investigator: Smith EB, **Yen A.** "Safety and Efficacy of Once-Daily AGN 190168 0.1% Gel or 0.05% Gel Versus Vehicle Gel in Stable Plaque Psoriasis," 1993-94.

Co-investigator: Raimer S, **Yen A.** "Safety and Efficacy Study of Topically Applied Doxepin HCL (5%) Triamcinolone Acetonide (0.25%) Cream Combination Compared to Doxepin (5%) Cream and Triamcinolone Acetonide (0.025%) for the treatment of Pruritic Atopic Dermatitis," 1993-95

Co-investigator: Raimer SS, **Yen A,** McCoy D, Christian M. "A Randomized, Dose Finding, Double Blind Comparison of Topically Applied Tacrolimus vs. Vehicle in Pediatric Patients with Atopic Dermatitis," 1995-96.

Co-investigator: Tyring SK, **Yen A,** Cardenas VJ. "Detection of Viral DNA Associated with Various Skin Diseases," 1993-1999.

Co-investigator: Tyring SK, **Yen A,** Lee P, Chopra K, Glidden A, Trizna Z. “A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Cidofovir Gel for the Treatment of Molluscum Contagiosum in Patients With HIV Infection,” 1997-1999.

Co-investigator: Tyring SK, **Yen A,** Lee P, Chopra K, Glidden A, Trizna Z. “A Randomized, Double Blind, Placebo-Controlled, Efficacy and Safety Study of Oral Lobucavir in Patients with Recurrent Herpes Labialis,” 1997-1999.

Co-investigator: Tyring SK, **Yen A,** Lee P, Chopra K, Glidden A, Trizna Z. “A Double-blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety of SmithKline Beecham Biologicals’ Herpes Simplex Candidate Vaccine (gD2t) with MPL and its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects with Genital Herpes Disease,” 1997-1999.

Co-investigator: Tyring SK, **Yen A,** Lee P, Chopra K, Glidden A, Trizna Z. “A Double-Blind, Randomized, Placebo-controlled, Study to Evaluate the Safety of SmithKline Beecham Biologicals’ Herpes Simplex Candidate Vaccine (gD2t) with MPL in HSV SeroPositive or SeroNegative Subjects without Genital Herpes Disease,” 1997-1999.

Co-investigator: Tyring SK, **Yen A,** Lee P, Chopra K, Glidden A, Trizna Z. “A Double-Masked, Double-dummy, Randomized, Acycovir-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Famciclovir with Acyclovir in the Treatment of Patients

with Ophthalmic Zoster,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “A Randomized, Double blind, Placebo Controlled Efficacy and Safety Study of Oral Lobucavir in Patients with Recurrent Genital Herpes,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “A Double-Blind, Multicenter Study Comparing Valacyclovir with Famciclovir for the Treatment of Uncomplicated Herpes Zoster in Immunocompetent Patients 50 Years of Age and Older,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “A Phase I/II Study of the Safety and Efficacy of Topical 1-(s)-(3-Hydroxy-2-phosphonyl-methoxypropyl) Cytosine Dihydrate (HPMPC) (Cidofovir) in the Treatment of Condyloma Acuminatum in Patients with HIV Infection,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “An Open-Label Study to Evaluate Famciclovir in the Management of Acute Uncomplicated Herpes Zoster in Persons Infected with HIV,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “Open-Label Trial Evaluating the Percutaneous Penetration of Imiquimod 5 Cream (Formulation U-2e) Following Overnight Application Three-Times Per Week for the Treatment of Genital-Perianal Warts,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “A Comparison of oral Valtrex 500 mg Twice Daily for Three or Five Days for Treatment of Recurrent Genital Herpes,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “A Double-Blind, Randomized, Parallel Group, Multi-Center Study, to Compare the Safety and Efficacy of 10 Days of Oral Famciclovir 750 mg Three Times a Day with Oral Valacyclovir 1 g Twice a Day in Reducing the Frequency of Subsequent Lesional Recurrences of HSV-2 in Patients Following Treatment of First Episode Genital HSV-2,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “Double-Blind, Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel with Acyclovir versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects with Acquired Immunodeficiency Syndrome (AIDS),” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “An Open Label Study to Evaluate the Effects of Chemical and Mechanical Methods of Skin Preparation Prior to Application of EMLA® Cream on the Absorbtion of Lidocaine and Prilocaine and on the Effectiveness of EMLA® Cream,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Chopra K, Glidden A, Trizna Z. “A Randomized Double-Blind, Double-Dummy Study to Assess the Efficacy and Safety of Oral Famciclovir for the Suppression of Recurrent Genital Herpes,” 1997-1999.

Co-investigator: Tyring SK, **Yen A**, Lee P, Evans T, Severson J. "Double-Blind, Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel with Acyclovir versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (GHSV) Infection in Subjects with Acquired Immunodeficiency Syndrome (AIDS)," 1997-1999.

Co-investigator: Tyring Sk, Lee P, Severson J, Evans T, **Yen A**. "Valacyclovir Therapy of Shingles in Immunocompetent Patients," 1997-1999.

Co-investigator: Tyring Sk, Lee P, Severson J, Evans T, **Yen A**. "Valacyclovir Therapy of Shingles in Immunocompromised Patients," 1997-1999.

OTHER RESEARCH PROJECTS:

Principal investigator: Moore A. "Oral Bexarotene and Narrowband UVB Phototherapy in the Treatment of Moderate-to-Severe Plaque Psoriasis," 2001-2003.

Principal investigator: Moore A. "Safety and Efficacy of Topical Tacrolimus for Vitiligo," 2000-2003.

Principal investigator: Moore A. "Safety and Efficacy of Topical Tacrolimus for Psoriasis," 2000-2003.

Principal investigator: Moore A. "Safety and Efficacy of Topical Betamethasone Valerate Foam 0.12%," 2000-2002.

Principal investigator: Moore A. "Immunohistochemical Analysis of the Expression of CD 117 in Dermatofibrosarcoma Protuberans," 2000-2002.

Principal investigator: Moore A. "Safety and Efficacy of Topical Imiquimod for Molluscum Contagiosum in Adults and Children," 1998-1999.

Principal investigator: Yen A, Sanchez RL. "Differentiation between Irritated Seborrheic Keratosis and Bowen's Disease With the Immunohistochemical Stains bcl-2 and p53," 1996-present.

Principal investigator: Yen A, Wagner RL, Moore T. "Effective Undermining and Fat Removal on Cone Defects Secondary to Linear Excisions," 1997-1999.

Co-investigator: Sanchez RL, Meyer W, Yen A, Herndon DN, Thompson, Hawkins H. "The Assessment of Mediators of Itching in Severely Burned Children: A Pilot Study." 1996-1999.

Principal investigator: Yen A, Walker D, Milligan T, Fergie J, Cardenas V Jr. "Typhus Infections: Diagnosis by Immunohistology and Polymerase Chain Reaction," 1995-1999.

Principal investigator: Yen A, Raimer SS, Brysk M, Rajaraman S, Smith EB, Cardenas V. "Treatment of Wounds and Ulcers with Autologous Tissue Grafts and Different Dressings",

1993-96.

Principal investigator: Yen A, Brysk M: Investigated the in vitro viability of epidermal cells upon the purified *Acetobacter xylinum* cellulose pellicle, 1993-94.

Co-investigator: Yen A, Brown M: Investigated the extrusion site as well as the nearby cell wall pore proteins and periplasmic particles of a unique cellulose by the G(-) bacterium *Acetobacter xylinum* through molecular distillation (in conjunction with Dr. Livesey and Dr. Linner in Houston), 1987-88.

Co-investigator: Yen A, Campion A: Utilization of Raman spectroscopy in investigating the interfacial interactions between the insulator polyamide and the semiconductor silicon, 1986.

Co-investigator: Yen A, Sanders B: Charting the Immunosuppression of Chickens with Avian Erythroleukemia Virus (AEV) utilizing PHA, concavalin A, and Pokeweed Mitogens, 1986.

PUBLICATIONS:

Book:

1. Tyring SK, **Yen-Moore A**, Eds. Mucocutaneous Manifestations of Viral Diseases. New York: Marcel Dekker, Inc., 2002.

Manuscripts:

1. **Yen A, Brown BM.** "Lattice Images and diffraction patterns of hercules graphite crystals by TEM after enhancement by a digital image processor" for Hercules, Inc., 5/88.
2. **Yen A, Tschen J, Robison D.** "Multiple tender, erythematous subcutaneous nodules on the lower extremities" (Case report on membranous fat necrosis). *Arch Derm* 1993; 129(10): 331-36.
3. **Yen A, Tschen J, Lowry L, Wolf J.E.** "Calcifying panniculitis and systemic calciphylaxis in an end-stage renal patient." *Cutis* 1993; 51(4): 245-47.
4. Friedman LC, Bruce S, Wineberg A, Cooper HP, **Yen A, Hill M.** "Early detection of skin cancer: racial/ethnic differences in behaviors and attitudes". *J Canc Educ* 1994; 9:42-47.
5. **Yen A, Bell T, Brysk H, Rajaraman S, Brysk M.** "Predesquamin extends maturation of cultured keratinocytes," *Exp Cell Res* 1994; 213:305-307.
6. **Yen A, Knipe RC, Tyring SK.** "Primary cutaneous blastomycosis: report of a case acquired by direct inoculation of a bullous pemphigoid lesion." *J Am Acad Derm* 1994; 31:277-278.
7. **Yen A, Black H, Tschen J.** "Effect of dietary omega-3 and omega-6 fatty acid sources on puva-induced cutaneous toxicity and tumorigenesis in the hairless mouse" *Arch Dermatol Res* 1994; 286:331-336.

8. **Yen A**, Grau-Massanes M, Sanchez R, Smith EB. "Elastoderma: a clinical mimic of acquired cutis laxa." *J Am Acad Derm* 1995;33:389-92.
9. Rady PL, **Yen A**, Rollefson JL, Orengo I, Bruce S, Hughes TK, Tyring SK. "Herpesvirus-like DNA sequences in Kaposi's and non-Kaposi's skin lesion of transplant patients." *Lancet* 1995;345:1339-1340.
10. Rady PL, **Yen A**, Martin III RW, Nedelcu I, Hughes TK, Tyring SK. "Herpes-like DNA sequences in classic Kaposi sarcomas." *J Med Virol* 1995;47:179-183.
11. **Yen A**, Sanchez R, Oblender M, Raimer SS. "Leukemia cutis: Darier's sign in a neonate with acute lymphoblastic leukemia." *J Am Acad Derm* 1996;34:375-8.
12. **Yen A**, Raimer SS. "Multiple painful blue nodules." (glomangioma) *Arch Derm* 1996;132(6):703-08.
13. Grau-Massanes M, Raimer S, Colome-Grimmer M, **Yen A**, Sanchez, R. "Congenital smooth muscle hamartoma presenting as a linear atrophic plaque" *J Pedi Derm* 1996;13(3):222-5.
14. **Yen A**, Cooper P, Weinberg A, Jackson M, Bruce S. "Workplace skin cancer screening after pre-screening questionnaires" *Skin Cancer* 1996; 11(2): 163-172.
15. Arany I, **Yen A**, Tyring SK. "p53, WAF1/CIP1 and mdm2 expression in skin lesions associated with human papillomavirus and human immunodeficiency virus" *Anticancer Research* 1997;17(2):1-5.
16. **Yen A**, Fearneyhough P, Raimer SS, Hudnall SD. "EBV-Associated Kikuchi's histiocytic necrotizing lymphadenitis with cutaneous manifestations" *J Am Acad Dermatol* 1997;36:342-6.
17. **Yen A**, Tschen J, Raimer S. "Mid-dermal elastolysis: report of a case in an adolescent following lesions resembling granuloma annulare" *J Am Acad Derm* 1997;37:870-2.
18. Yen A, Fearneyhough, Rady P, Tyring S, Diven D. "Erythema Induratum of bazin as a tuberculid: confirmation of mycobacterium tuberculosis DNA polymerase chain reaction analysis" *J Am Acad Dermatol* 1997;36:99-101.
19. **Yen A**, Sanchez RL, Fearneyhough P, Tschen J, Wagner R. "Mucoepidermoid carcinoma with cutaneous presentation" *J Am Acad Derm* 1997;37:340-2.
20. Payne D, **Yen A**, Tyring SK. "Coinfection of molluscum contagiosum with human papillomavirus" *J Am Acad Dermatol* 1997;36:641-644.
21. **Yen A**, McMichael A, Kilkenny M, Rotstein H. "Mycosis fungoides: an Australian experience" *Austr J Dermatol* 1997; 38: (Suppl.) S86-S90.
22. **Yen A**, Rady PL, Cortes-Franco R, Tyring SK. "Detection of mycobacterium tuberculosis

- DNA in erythema induratum of bazin using polymerase chain reaction" *Arch Dermatol* 1997;133:532-533.
23. **Yen A**, Sanchez RL, Raimer SS. "Papular mucinosis associated with acquired immunodeficiency syndrome: response to isotretinoin" *J Am Acad Derm* 1997;37:127-8.
 24. Apisarnthanarax N*, Payne D, **Yen A**, Tyring SK. "Failure to detect human papillomavirus in cutaneous molluscum contagiosum lesions" *Anticancer Research*, 17(6D):4781-2, 1997.
 25. Memar OM*, Rady PL, Goldblum RM, **Yen A**, West AB, Tyring SK. "Detection of human herpesvirus-8 in blistering skin from patients with pemphigus" *Arch Dermatol* 1997;133:1247-51.
 26. Rady PL, Hodak E, **Yen A**, Memar O, , Trattner A, Feinmesser M, David M, Hudnall SD, Tyring SK. "Detection of human herpesvirus-8 DNA in Kaposi's sarcomas from iatrogenically immunosuppressed patients" *J Am Acad Derm* 1998;38:429-37.
 27. Moore TO*, **Moore A Yen**, Langer M, Wagner RF. "Tumor remnants within giant cells following irradiation of cutaneous squamous cell carcinoma" *Dermatologic Surgery*, 24(10):1094-6, 1998.
 28. Brown T*, **Yen A**. "Isolation of mycobacterium avium complex from erythema multiforme" *J Am Acad Derm*, 39(3):193-5, 1998.
 29. Brown, T.J., **A. Yen-Moore**, and S.K. Tyring. An overview of sexually transmitted diseases Part I (bacterial STDs). *J. Am. Acad. Dermatol.* 41:511-529; 1999.
 30. Brown, T.J., **A. Yen-Moore**, and S.K. Tyring. An overview of sexually transmitted diseases Part II (viral STDs). *J. Am. Acad. Dermatol.* 41:661-677; 1999.
 31. Waguespack-Labiche J*, Chen SH*, **Yen A**. "Disseminated congenital candidiasis in a premature infant" *Arch of Dermatol*, 135(5):510-2, 1999.
 32. Czelusta A*, **Moore A Yen**. "Cutaneous mycobacterium kansasii infection in a patient with SLE: Case Report and Review." *J Am Acad Dermatol*, 40(2 Pt 2):359-63, 1999.
 33. Czelusta AJ, **Yen-Moore A**, Evans TY, Tyring SK. "Sexually transmitted diseases." *J Am Acad Dermatol*, 41:614-23, 1999.
 34. Czelusta, A., **A. Yen-Moore**, M. Vander Straten, D. Carrasco, and S.K. Tyring. An overview of sexually transmitted diseases Part III. Sexually transmitted diseases in HIV infected patients. *J. Am. Acad. Dermatol.* 43:409-432; 2000.
 35. **Yen-Moore, A.**, S.D. Hudnall, P.L. Rady, R.F. Wagner, T.O. Moore, O. Memar, T.K. Hughes, and S.K. Tyring. Differential expression of the HHV-8 vGCR cellular homolog gene in AIDS-associated and classic Kaposi's Sarcoma: Potential role of HIV-1 Tat. *Virology* 267:247-251; 2000.

36. **Yen-Moore, A.**, M. Vander Straten, D. Carrasco, T.Y. Evans, and S.K. Tying. Cutaneous viral infections in HIV-infected individuals. *Clinics in Dermatology*. 18:423-432; 2000.
37. Stambaugh HL*, Chen SW*, **Yen A.** "Staphylococcal scalded skin syndrome in adults: case report and review" submitted for publication, *J Am Acad Derm*, 2000.
38. **Yen A**, Rady PL, Rollefson JL, Orengo I, Bruce S, Hughes TK, Tying SK. "Prevalence of HPV, EBV, and human herpes virus 8 in proliferative lesions and carcinomas from organ transplant patients and in Kaposi's sarcoma" submitted for publication, *Arch Dermatol*, 2000.
39. **Yen A**, Rady PL, Wagner Jr R, Memar O, Tying SK. "Detection of HHV-8 transcription in cutaneous carcinomas from immunocompetent patients." submitted for publication, *Arch Dermatol*, 2000.
40. **Yen-Moore A.** Vander Straten M. Carrasco D. Evans TY. Tying SK. "Cutaneous viral infections in HIV-infected individuals." *Clinics in Dermatology*. 18(4):423-32, 2000.
41. Moore,T. O.*, **A. Yen-Moore**, D. Carrasco, M. Vander Straten, I. Arany, W. Au, and S.K. Tying. "Human papillomavirus, smoking and cancer." *J. Cutan. Med. Surg.* 5:323-328; 2001.
42. Christian MM*. Moy RL. Wagner RF. **Yen-Moore A.** A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma. *Dermatologic Surgery*. 27(5):441-5, 2001.
43. Maitra A*, Gazdar AF, Moore TO, **Moore AY.** "Loss of Heterozygosity Analysis of Cutaneous Melanoma and Benign Melanocytic Nevi: Laser Capture Microdissection Demonstrates Clonal Genetic Changes in Acquired Nevocellular Nevi." *Hum Pathol*. 2002 Feb;33(2):191-7.
44. Moore TO*, **Moore AY.** "Fournier's gangrene: A dermatologic emergency" submitted for publication.
45. Czelusta A*, **Moore A Yen.** "Cytophagic histiocytic panniculitis presenting with cutaneous and pulmonary involvement" submitted for publication.
46. Moore TO*, **Moore AY**, Wagner RF. "Removal of Burrow's triangles compared with lipoplasty for correction of cone defects during closure of linear excisions." in progress.
47. **Yen A**, Austin P, Sanchez RL. "Is bowenoid seborrheic keratosis a form fruste of squamous cell carcinoma in situ?" in progress.
48. Ubaradka G. Sathyanarayana, **Angela Yen Moore**, Lin Li, Asha Padar, Kuntal Majmudar, Victor Stastny, Prakash Makarla, Makoto Suzuki, John D. Minna, Ziding Feng, and Adi F. Gazdar, "Sun Exposure Related Methylation in Malignant and Non-Malignant Skin Lesions," Submitted to *Clinical Cancer Research*, October, 2005

49. Tyring, Stephen; Berger, Tim; **Yen-Moore, Angela**; Tharp, Michael; Hamed, Kamal, "Single-Day Therapy for Recurrent Genital Herpes" *American Journal of Clinical Dermatology*, Volume 7, Number 4, 2006, pp. 209-211.
50. **Moore A**, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. "A Randomized, Open-Label Trial Of Continuous Versus Interrupted Etanercept Therapy In The Treatment Of Psoriasis," *Journal of the American Academy of Dermatology*, April 2007 Vol. 56, Issue 4, Pages 598-603.
51. Sathyanarayana, Ubaradka G., Moore, Angela Yen, Li, Lin, Padar, Asha, Majmudar, Kuntal, Stastny, Victor, Makarla, Prakash, Suzuki, Makoto, Minna, John D., Feng, Zinding, Gazdar, Adi F. "Sun Exposure Related Methylation in Malignant and Non-malignant Skin Lesions" *Cancer Letters* 245 (2007) 112-120.

*in-training

Abstracts and Letters:

1. **Yen A**, Lotzova E. "Cytotoxic & growth profiles of natural killer cells," (Abstract) Summer Student '85 Research Programs at the MD Anderson/ UT Houston Cancer Center, 1985.
2. **Yen A**, Raimer SS. "Occlusion of Potent Topical Steroids." (Letter) *Arch Dermatol* 1995;131:227.
3. **Yen A**, Sanchez RL, Diven D. "Erythema induratum as a tuberculid" (Abstract) *Southern Medical Journal* 1995;S32:88.
4. Tyring, S.K., P. Rady, **A. Yen**, and T.K. Hughes. HHV8 and skin cancers in immunosuppressed patients. *Lancet* 347:339; 1996
5. **Yen A**, Rady PL, Hudnall SD, Sellers R, Wagner R, Orengo I, Bruce S, Tyring SK. "Prevalence of human herpesvirus 8 in cutaneous neoplasms". (Abstract) *J Invest Med* 1996;44(1);51A.
6. **Yen A**, Rady PL, Hudnall SD, Sellers R, Wagner R, Orengo I, Bruce S, Tyring SK. "Prevalence of human herpesvirus 8 DNA in Kaposi's sarcoma, carcinomas, and post-transplant squamous lesions." (Abstract) *J Invest Dermatol* 1996;106(4):844.
7. Sanchez RL, **Yen A**. (Letter) "Elastoderma". *J Am Acad Derm* 1996;34(6):1093.
8. Rady PL, Hodak E, **Yen A**, Hudnall SD, Trattner A, Feinmesser M, David M, Gaspari AA, Memar O, Tyring SK. "Detection of HHV-8 DNA in Kaposi's sarcomas from immunosuppressed patients." (Abstract) *JAIDS and HR* 1997;14(4):A23.
9. **Yen A**, Austin P, Sanchez RL. "Is bowenoid seborrheic keratosis a form of squamous cell carcinoma in situ?" (Abstract) *J Cut Pathol* 24 (2): 133; 1997.
10. Memar, O.M., P.L. Rady, R.M. Goldblum, A.B. West, **A. Yen**, and S.K. Tyring. Human

herpesvirus 8 DNA sequences in a patient with pemphigus vulgaris, but without HIV infection or Kaposi's sarcoma. *J. Invest. Dermatol.* 108:118-119; 1997.

11. **Yen A**, Austin P, Sanchez RL. "Is bowenoid seborrheic keratosis a form fruste of squamous cell carcinoma in situ?" (Abstract) *Dermatol Surg* 1997;23:669-72.
12. **Yen A**, Rady P, Memar O, Hodak E, Trattner A, Feinmesser M, David M, Tyring SK. "Human herpesvirus 8 (HHV-8) in cutaneous malignant and autoimmune lesions: sequence variability of HHV-8 DNA in Kaposi's sarcoma, squamous carcinomas, and pemphigus" (Abstract) *Australasian J Derm* 1997;38(Supp 2):22-23.
13. **Yen A**, Rady PL, Moore TO, Tyring SK. "Human herpesvirus 8 (HHV-8) cellular homologue genes in Kaposi's sarcoma" (Abstract) *J Invest Dermatol* 1998;110(4): 484.
14. Rady, P.L., S.D. Hudnall, **A. Yen**, T.K. Hughes, and S.K. Tyring. Expression of human herpesvirus 8 (HHV-8) cellular homologue genes in classic and AIDS related Kaposi's sarcomas. (Abstract) *J. AIDS & H.R.* 17:A21; 1998.
15. **Moore AY**. "Active transcription of human herpesvirus 8 cellular homologue genes and HIV-1 tat in various form with Kaposi's sarcosis." *J Am Acad Dermatol*, 1999;41(3 Pt 1):458-9.
16. Chiles LR. Christian MM. McCoy DK. Hawkins HK. **Yen AH**. Raimer SS. "Langerhans cell histiocytosis in a child while in remission for acute lymphocytic leukemia." *Journal of the American Academy of Dermatology.* 45(6 Suppl):S233-4, 2001.
17. Moore TO*, McCarty T, Kuhn J, Maitra A, Gazdar A, **Moore AY**. "Loss of Heterozygosity at 6q22-23.3 in Congenital Nevi, Acquired Nevi, and Cutaneous Melanoma After Laser Capture Microdissection" *Ann Surg Oncol*, 2002;9(1):S36.
18. Mei-shu Li, Ajay Goel, **Angela Moore**, Todd Moore, and C. Richard Boland, "Mutational Signatures of Abnormal DNA Mismatch Repair (MMR) in Sebaceous Neoplasms." (Abstract), Joint ASCO, AGA, ASTRO, and SSO Meeting on GI Cancers, San Francisco, January, 2006.

Chapters:

1. **Yen A**. "Scleredema." Demis DJ, Thiers BH, Burgdorf WH, Raimer SS. (Eds) *Clinical Dermatology*. JB Lippincott Co: Philadelphia, 1997,(2) 8-17:1-4.
2. **Yen A**, Tyring SK. "Tumor-Stromal Interactions in Cutaneous Carcinogenesis." Miller SJ, Maloney ME (Eds) *Cutaneous Oncology: Pathophysiology, Diagnosis and Treatment*. Blackwell Science, Inc: Cambridge, 1998, 98-104.
3. **Yen A**, Hudnall SD. "Kikuchi's Syndrome." Demis DJ, Thiers BH, Burgdorf WH, Raimer SS (Eds) *Clinical Dermatology*. J B Lippincott Co: Philadelphia, 1997,(3) 14-24:1-5.
4. **Yen-Moore, A., R. Vinik, and S.K. Tyring**. Human papillomavirus transmission and

epidemiology patterns. In: *Proceedings of the Fourth International Multidisciplinary Congress: Eurogin 2000*. Ed.: J. Monsonago. Monduzzi Editore, Bologna, Italy, pp. (suppl.) 6-17; 2000.

5. **Yen-Moore, A.**, and S.K. Tyring. Cutaneous warts. In: *Human Papillomaviruses: Clinical and Scientific Advances*. Eds.: J.C. Sterling and S.K. Tyring. Oxford University Press, London, U.K. pp. 52-59; 2001.
6. Walling DM, **Yen A**, Hudnall SD. "Epstein-Barr Virus." Tyring SK. (Ed) Cutaneous Manifestions of Viral Diseases. W.B. Saunders Co: Philadelphia. (in press)
7. Brown, T., **A. Yen-Moore**, and S.K. Tyring. Herpes virus 7. In: *Mucocutaneous Manifestations of Viral Diseases*. Ed.: S.K. Tyring. Marcel Dekker, New York (in press).
8. Brown, T., **A. Yen-Moore**, and S.K. Tyring. Herpes virus 8. In: *Mucocutaneous Manifestations of Viral Diseases*. Ed.: S.K. Tyring. Marcel Dekker, New York (in press).
9. **Yen A**. "Chapter XVIII: Sebaceous Gland Tumors, Eccrine Gland Tumors, Apocrine Gland Tumors." Sanchez RL, Raimer SS (Eds) Dermatopathology Primer. (in press).
7. Severson J*, **Yen A**. "Viral Diseases in Dermatology: An Update" Rakel RE (Eds) Conn's Current Therapy. W. B. Saunders Co: Philadelphia. (in press)

* in-training

PRESENTATIONS:

Invited Presentations

1. Rady P, Yen A, Bruce S, Hughes TK, Tyring SK. "HHV-8/KSHV DNA sequences in Kaposi's and non-Kaposi's skin lesions of transplant patients" at the Annual Meeting of the Laboratory of Tumor Cell Biology of the NCI, August, 1995.
2. Yen A, Raimer SS. "Case Report and Review of Kikuchi's Histiocytic Necrotizing Lymphadenitis" at Xian Medical School, Xian, China, October, 1995.
3. Yen A, Raimer SS. "Case Report and Review of Elastoderma: A Clinical Mimic of Acquired Cutis Laxa" at Xian Medical School, Xian, China, October, 1995.
4. Yen A, Raimer SS. "Case Report of Leukemia Cutis Presenting with Darier's Sign in an Infant with Acute Lymphoblastic Leukemia" at Xian Medical School, Xian, China, October, 1995.
5. Rady P, Hudnall SD, Hodak E, Trattner A, Feinmesser M, David M, Sellers R, Yen A, Memar O, Tyring SK. "Presence of Human Herpesvirus-8 DNA in Kaposi's sarcomas from Patients Treated with Corticosteroids" at the First International Kaposi's Sarcoma Meeting, Santa Monica, CA, May, 1996.

6. Rady P, Hodak E, Yen A, Hudnall D, Trattner A, Feinmesser M, David M, Sellers R, Memar O, Tyring SK. "HHV-8 DNA in Kaposi's Sarcomas from Patients Treated with Corticosteroids," at the Institute of Human Virology Annual Meeting, September, 1996.
7. Rady, P., S.D. Hudnall, A. Yen, T.K. Hughes, and S.K. Tyring. Frequency of human herpesvirus 8 (HHV-8) cellular homologue gene expression in Kaposi's sarcomas (KS) and BCBL-1 cells. Second Annual Meeting, Institute of Human Virology, Baltimore; Sept. 15-21, 1997.
8. Yen A. "Cutaneous Manifestations of Herpesviruses 4 Through 8" at the 19th World Congress of Dermatology, Sydney, Australia, June, 1997.
9. Yen A. "Human Herpesviruses" at the Texas Dermatological Society Meeting, Galveston, Texas, October, 1997.
10. Moore A. "Human Herpes Viruses" at The Global Partners 1999 Sino-American Medical Exchange Conference, Shenyang, China, June 1999.
11. Moore A. "Palisaded Granulomatous Dermatitis" at the 13th Combined Skin Pathology Course, Dallas, Texas, October, 1998.
12. Moore A. "Special Stains" at the 13th Combined Skin Pathology Course, Dallas, Texas, October, 1998.
13. Moore A. "Pitfalls in Malignant Melanoma Diagnosis" at the 13th Combined Skin Pathology Course, Dallas, Texas, October, 1998.
14. Moore A. "Pitfalls in the Diagnosis of Melanoma" at the 5th Annual Dermatopathology Review Course, Galveston, Texas, 1999.
15. Yen-Moore A. "Human Herpesviruses 4 through 8," American Academy of Dermatology, San Francisco, CA, March, 2000.
16. Moore, AY. "Skin cancer prevention and diagnosis" at the Health Symposium 2000, Arlington Cancer Research Foundation, Arlington, Texas, February, 2000.
17. Moore AY. "Basic Self-Assessment Course in Dermatopathology," American Academy of Dermatology, Washington DC, March, 2001.

International Presentations

1. Rady PL, Yen A, Rollefson JL, Orengo I, Bruce S, Hughes TK, Tyring SK. "Presence of human papillomavirus, Epstein Barr virus and Kaposi's sarcoma associated herpesvirus like DNA in skin lesions from organ transplant patients. 14th International Papillomavirus Conference in Quebec City, Canada, June, 1995.
2. Yen A, Fearneyhough P, Hudnall D, Raimer SS. "Kikuchi's Histiocytic Necrotizing

- Lymphadenitis" at the Third International Symposium on Cutaneous Fungal, Bacterial, and Viral Infection and Therapy Meeting, San Francisco, CA, September, 1995.
3. Rady PL, Yen A, Martin RW, Nedelcu I, Hughes TK, Orengo I, Bruce S, Tyring SK. "Herpes Virus-like DNA Sequences in Kaposi's and Non Kaposi's Skin Lesions", Third International Symposium on Cutaneous Fungal, Bacterial and Viral Infection and Therapy, San Francisco, CA, September, 1995.
 4. Rady P, Hodak I, Yen A, Trattner A, Feinmesser M, David M, Memar OM, Tyring SK. "Presence of HHV-8 in Kaposi's Sarcomas from Iatrogenically Immunosuppressed Patients" at the Convergence of AIDS and Cancer Research, 1st International Conference of the Mor Kaposi Research Foundation, Budapest, Hungary, August, 1996.
 5. Yen A, Rady P, Memar O, Hodak E, Trattner A, Feinmesser M, David M, Tyring SK. "Human Herpesvirus 8 (HHV-8) in Cutaneous Malignant and Autoimmune Lesions: Sequence Variability of HHV-8 DNA in Kaposi's Sarcoma, Squamous Carcinomas, and Pemphigus" at the 19th World Congress of Dermatology, Sydney, Australia, June, 1997.
 6. Moore AY, Rady PL, Hudnall SD, Moore TO, Wagner RF, Tyring SK. "Expression of Human Herpesvirus 8 Cellular Homologue Genes in Kaposi's Sarcoma" at the 1998 International Investigative Dermatology Meeting in Cologne, Germany, May, 1998.
 7. Moore AY, Rady PL, Hudnall SD, Moore TO, Wagner RF, Tyring SK. "Expression of Human Herpesvirus 8 Cellular Homologue Genes in Kaposi's Sarcoma" at Clinical Dermatology 2000 Singapore Meeting in Singapore, June, 1998.
 8. Moore AY, Moore TO. "Human herpesviruses" at The Global Partners 1999 Sino-American Medical Exchange Conference in Shenyang, China, June 1999.
 9. Moore TO, Yen-Moore A. "Fournier's Gangrene: A Dermatologic Emergency" at The Global Partners 1999 Sino-American Medical Exchange Conference in Shenyang, China, June 1999.
 10. Moore TO, Yen-Moore A. "Nasopharyngeal Carcinoma: Role of Endoscopic Guided Resection" at The Global Partners 1999 Sino-American Medical Exchange Conference in Shenyang, China, June 1999.
 11. Moore TO, Yen-Moore A. "Role of Sentinel Lymph Node Dissection in Intermediate-thickness Melanomas" at The Global Partners 1999 Sino-American Medical Exchange Conference in Shenyang, China, June 1999.
 12. Angela Yen Moore, "Sun Exposure Related Methylation in Malignant and Non-Malignant Skin Lesions" the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7, 2006.
 13. Angela Yen Moore, "Alefacept, Acitretin, and Narrowband UVB Combination Therapy for Plaque-Type Psoriasis Allows Faster Withdrawal and Shortens Onset of Action." the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7,

2006.

14. Angela Yen Moore, "Alefcept and Low-Dose Acitretin Therapy for Inverse Psoriasis and Palmar/Plantar Psoriasis Shortens Onset of Action." the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7, 2006.
15. Angela Yen Moore, "Alefcept and Narrowband UVB Combination Therapy for Psoriasis Shortens Onset of Action." the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7, 2006.
16. Angela Yen Moore, "Etanercept and Narrowband UVB Combination Therapy for Plaque-Type Psoriasis Shortens Onset of Action in Both Adults and Children." the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7, 2006.
17. Angela Yen Moore, "Low-Dose Acitretin Therapy in Combination with Biologic and Narrowband UVB Therapy for Psoriasis Subtypes in Adults and Children Increases Efficiency and Shortens Onset of Action Without Increased Side." the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7, 2006.
18. Angela Yen Moore, "Viral Infections: Update on Herpes Simplex Viruses." the 64th Annual Meeting of the American Academy of Dermatology, San Francisco, Ca. Mar. 3-7, 2006.
19. Angela Yen Moore, "Imiquimod: Mechanism of Action and Application of Imiquimod in Keloids,": Hangzhou, China, June, 2006.
20. Oral presentation on "Imiquimod (Aldara):Experience of a U.S. Dermatologist" Beijing, China, August, 2007.
21. Oral presentation on "Imiquimod (Aldara):Experience of a U.S. Dermatologist" Guangzhou, China, August, 2007.
22. Oral presentation on "Imiquimod (Aldara):Experience of a U.S. Dermatologist" Ningbo, China, August, 2007.
23. Oral presentation on "Imiquimod (Aldara):Experience of a U.S. Dermatologist" Nanjing, China, August, 2007.
24. Oral presentation on "Imiquimod (Aldara):Experience of a U.S. Dermatologist" Beijing, Nanjing and Guangzhou, China, August, 2007.
25. Oral presentation on "Experience with Dovobet by a U.S. Dermatologist" Beijing, China, August, 2007.
26. Oral presentation on "Experience with Dovobet by a U.S. Dermatologist" Ningbo, China, August, 2007.

27. Oral presentations with Dr. Stephen Tyring "An Update On The Treatment And Prevention Of Viral Diseases" And "Human Papillomaviruses: Viral Oncogenesis." Facultad de Ciencias Farmaceuticas y Bioquimicas (Faculty of Pharmacy and Biochemistry), Universidad Mayor de San Andres, La Paz, Bolivia, September 27, 2007.
28. Oral Presentation "Antiviral Therapies: State Of The Art, New Drugs And Vaccines" the 21st World Congress of Dermatology, Buenos Aires, Argentina. September 30-October 5, 2007.
29. Angela Yen Moore, "Short Contact Therapy With Topical 5-Fu And Cryosurgery For Actinic Keratoses" the 21st World Congress of Dermatology, Buenos Aires, Argentina. September 30-October 5, 2007.
30. Angela Yen Moore, "Alefcept And Low-Dose Acitretin Therapy For Inverse Psoriasis And Palmar/Plantar Psoriasis Shortens Onset Of Action" the 21st World Congress of Dermatology, Buenos Aires, Argentina. September 30-October 5, 2007.
31. Angela Yen Moore, "Alefcept, Acitretin, And Narrowband UVB Combination Therapy For Plaque-Type Psoriasis Allows Faster Withdrawal And Shortens Onset Of Action" the 21st World Congress of Dermatology, Buenos Aires, Argentina. September 30-October 5, 2007.
32. Angela Yen Moore, "Alefcept and Narrowband UVB Combination Therapy for Psoriasis Shortens Onset of Action" the 21st World Congress of Dermatology, Buenos Aires, Argentina. September 30-October 5, 2007.
33. Oral presentations "Antiviral therapies: state of the art, new drugs and vaccines" International Meeting Fronteiras da Dermatologia hosted by the Brazilian Society of Dermatology Officers, Rio de Janero, Brazil, October 7, 2007.
34. Oral presentations "Virosis Emergentes" International Meeting XVII Congreso Iberolatinoamericano de Dematologia, Quito, Ecuador, October 10, 2008.

National Presentations

1. Yen A, Tschen J, Black H. "Effect of Dietary Omega-3 and Omega-6 Fatty Acid Sources on Induction of Inflammation and Ornithine Decarboxylase Activity in the Hairless by Psoralen and Longwave Ultraviolet Light at the Society of Investigative Dermatology Meeting in Baltimore, Maryland, April, 1992.
2. Oral presentation on "Predesquamin Extends Maturation of Keratinocytes" at the National Student Research Forum, Galveston, Texas, April, 1994.
3. Yen A, Bruce S. "Skin Cancer Screening at the Workplace: Prescreening Questionnaire Targeted at High Risk Patients" at the Summer American Academy of Dermatology Meeting at San Francisco, CA, August, 1994.
4. Yen A, Murphy C, Knipe RC, Tyring SK. "Primary Cutaneous Blastomycosis" at the

- Summer American Academy of Dermatology Meeting at San Francisco, CA, August, 1994.
5. Yen A, Brysk M, Brysk H, Bell T, Rajaraman S. "Predesquamin Extends Maturation of Cultured Keratinocytes" at the Summer American Academy of Dermatology Meeting at San Francisco, CA, August, 1994.
 6. Oral presentation on "Effect of Dietary Omega-3 and Omega-6 Fatty Acid Sources on Induction of Inflammation and Ornithine Decarboxylase Activity in the Hairless Mouse by Psoralen and Longwave Ultraviolet Light" at the Summer American Academy of Dermatology Meeting at San Francisco, CA, August, 1994.
 7. Oral presentation on "Elastoderma: A Clinical Mimic of Acquired Cutis Laxa" at the 53rd Annual American Academy of Dermatology Meeting at New Orleans, LA, February, 1995.
 8. Oral presentation on "Effect of Dietary Lipids on PUVA Photocarcinogenesis in the Hairless Mouse" at the Residents and Fellows Research Symposium at the 53rd Annual American Academy of Dermatology Meeting in New Orleans, LA, February, 1995.
 9. Oral presentation on "Workplace Skin Cancer Screening After Pre-Screening Questionnaires" at the National Student Research Forum at Galveston, Texas, April, 1995.
 10. Oral presentation on "Leukemia cutis: Darier's sign in a Neonate with Acute Lymphoblastic Leukemia" at the Pediatric Dermatology Society Meeting, Vancouver, Canada, June, 1995.
 11. Yen A, Fearneyhough P, Hudnall D, Raimer SS. "Cutaneous Manifestations of EBV-Associated Kikuchi's Disease" at the Pediatric Dermatology Society Meeting, Vancouver, Canada, June, 1995.
 12. Yen A, Grau-Massanes M, Sanchez RL, Colume-Grimmer M, Raimer SS. "Congenital Smooth Muscle Hamartoma Presenting as a Linear Atrophic Plaque" at the Pediatric Dermatology Society Meeting, Vancouver, Canada, June, 1995.
 13. Rady, P.L., A. Yen, R.W. Martin, I. Nedelcu, T.K. Hughes, I. Orengo, S. Bruce, and S.K. Tyring. Herpesvirus-like DNA sequences in Kaposi's and non-Kaposi's skin lesions. Third International Symposium on Cutaneous Fungal, Bacterial, and Viral Infection and Therapy, San Francisco; Sept. 14-19, 1995.
 14. Rady PL, Yen A, Martin RW, Nedelcu I, Hughes TK, Tyring SK. "Herpesvirus-like DNA Sequences in Classic Kaposi's Sarcomas" at the Infectious Diseases Society of America, San Francisco, September, 1995.
 15. Yen, A., P.L. Rady, A. Jones, R. Sellers, I. Orengo, S. Bruce, R. Wagner, Jr., and S.K. Tyring. Prevalence of HHV-8 in cutaneous neoplasms. Society for Investigative Dermatology, Southern Regional Meeting, New Orleans; Jan. 31-Feb. 2, 1996; J. Invest. Med. 44:51A; 1996.
 16. Yen A, Rady PL, Hughes TK, Orengo I, Bruce S, Wagner R, Tyring SK. "HHV-8 DNA Sequences in Skin Lesions of Immunocompromised and Immunocompetent Patients." at the

- 54th Annual American Academy of Dermatology, Washington, D.C., February, 1996.
17. Yen A, Fearneyhough P, Hudnall SD, Raimer S. "Cutaneous Manifestations of EBV-Associated Kikuchi's Disease." at the 54th Annual American Academy of Dermatology, Washington, DC, February, 1996.
 18. Oral presentation of "HHV-8 DNA Sequences in Skin Lesions of Immunocompromised and Immunocompetent Patients" at the Residents and Fellows Symposium at the 54th Annual American Academy of Dermatology, Washington, DC, February, 1996.
 19. Hudnall SD, Sellers R, Yen A, Rady PL, Tyring SK. "Detection of Kaposi's Sarcoma Associated Herpesvirus (HHV-8) DNA by In-Situ Hybridization in Kaposi's Sarcoma and Post-Transplant Squamous Lesions: Evidence of Infection of both Kaposi's Sarcoma Tissue and Squamous Epithelium" at the United States and Canadian Academy of Pathology, Washington, DC, March, 1996.
 20. Yen, A., P. Rady, I. Orengo, S. Bruce, R.F. Wagner, Jr., and S.K. Tyring. Prevalence of HHV-8 in cutaneous neoplasms. J.W. McLaughlin Fellowship Fund Research Colloquium, UTMB, Galveston;; March 26, 1996.
 21. Oral presentation of "Prevalence of HHV-8 in Cutaneous Sarcomas and Carcinomas" at the 37th Annual National Student Research Forum at Galveston, Texas, April, 1996.
 22. Oral presentation on "Prevalence of Human Herpesvirus 8 DNA in Kaposi's Sarcoma, Carcinomas, and Post-transplant Squamous Lesions" at the 57th Annual Society for Investigative Dermatology Meeting, Washington, DC., May, 1996.
 23. Yen A, Rady P, Hodak E, Hudnall D, Sellers R, Orengo I, Bruce S, Trattner A, Feinmesser M, David M, Tyring SK. "Prevalence of Human Herpesvirus 8 DNA in Kaposi's Sarcoma from Patients during Corticosteroid Therapy" at the Summer American Academy of Dermatology Meeting in Orlando, Florida, July, 1996.
 24. Oral presentation on "Human Herpesvirus 8 (HHV-8) in Cutaneous Malignant and Autoimmune Lesions: Prevalence of HHV-8 in Kaposi's Sarcoma, Squamous Carcinomas, and Pemphigus" at the Residents and Fellows Symposium at the 55th Annual American Academy of Dermatology Meeting in San Francisco, California, March, 1997.
 25. Oral presentation on "Detection of Human Herpes Virus-8 DNA Sequences in Blistering Skin, Normal Skin, and Blood of a Patient with Pemphigus Vulgaris, But Without HIV Infection or Kaposi's Sarcoma" at the 55th Annual American Academy of Dermatology Meeting in San Francisco, California, March, 1997.
 26. Yen A, Austin P, Sanchez RL. "Is Bowenoid Seborrhic Keratosis a Form of SCC In-Situ?" at the 34th Annual Meeting of the American Society of Dermatopathology, San Francisco, California, March, 1997.
 27. Yen A, Rady PL, Memar O, Hodak E, Trattner A, Feinmesser M, David M, Tyring SK. "Human Herpesvirus 8 in Cutaneous Malignant and Autoimmune Lesions: Prevalence of

- HHV-8 in Kaposi's Sarcomas, Squamous Carcinomas, and Pemphigus" at the 55th Annual American Academy of Dermatology Meeting in San Francisco, California, March, 1997.
28. Yen A, Rady PL, Cortes-Franco R, Tyring SK. "PCR Detection of Mycobacterium Tuberculosis DNA in Case Series of Erythema Induratum" at the 55th Annual American Academy of Dermatology Meeting in San Francisco, California, March, 1997.
 29. Arany I, Yen A, Tyring SK. "p53, WAF1/CIP 1 and Mdm2 Expression in Skin Lesions Associated with Human Papillomavirus and Human Immunodeficiency Virus" at the 55th Annual American Academy of Dermatology Meeting in San Francisco, California, March, 1997.
 30. Rady P, Hodak E, Yen A, Memar O, Trattner A, Feinmesser M, David M, Tyring SK. "Human Herpesvirus 8 (HHV-8) in Cutaneous Malignant and Autoimmune Lesions" at the 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April, 1997.
 28. Arany, Yen A, Tyring SK. "Status of p53 and WAF1/CIP1 in Anogenital Lesions Harboring Human Papillomavirus and Human Immunodeficiency Virus" at the 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA, April, 1997.
 29. Yen A, Rady PL, Memar O, Tyring SK. "Coexistent Expression of Interleukin 8 (IL-8) and IL-8 Receptors With Human Herpesvirus 8 (HHV-8) in Kaposi's Sarcoma" at the Society for Investigative Dermatology 58th Annual Meeting, Washington, D.C., April, 1997.
 30. Yen A, Rady PL, Moore T, Memar O, Tyring SK. "Expression of Human Herpesvirus * (HHV-8), HHV-8 Homologues of Cyclin D and G Protein-Coupled Receptor, Human Interleukin 8 (IL-8), and Human IL-8 Receptor in Kaposi's Sarcoma" at the Summer American Academy of Dermatology Meeting, New York City, NY, August, 1997.
 31. Rady PL, Hudnall SD, Yen A, Hughes TK, Tyring SK. "Frequency of Human Herpesvirus 8 (HHV-8) Cellular Homologue Gene Expression in Kaposi's Sarcomas (KS) and BCBL-1 Cells" at the Institute of Human Virology 1997 Annual Meeting, Baltimore, MD, September, 1997.
 32. Yen A, Rady PL, Tyring SK. "Comparative Expression of Human Herpesvirus 8 (HHV-8) Homologues of Cyclin D (Latency Phase) and Macrophage Inflammatory Protein II (Lytic Phase) with Small Nuclear RNA T0.7 in Kaposi's Sarcoma" at the American Academy of Dermatology 56th Annual Meeting, Orlando, FL, February, 1998.
 33. Moore T*, Yen A. "Fournier's Gangrene: A Dermatologic Emergency" at the American Academy of Dermatology 56th Annual Meeting, Orlando, FL, February, 1998.
 34. Moore T*, Yen A, Wagner R. "The Histopathology of Irradiated Cutaneous Squamous Cell Carcinoma" at the American Academy of Dermatology 56th Annual Meeting, Orlando, FL, February, 1998.
 35. Yen A, Rady PL, Hudnall SD, Hughes TK, Tyring SK. "Expression of Human Herpesvirus

- 8 (HHV-8) Cellular Homologue Genes in Kaposi's Sarcomas and BCBL-1 Cell Lines" at the American Academy of Dermatology 56th Annual Meeting, Orlando, FL, February, 1998.
36. Rady, P.L., S.D. Hudnall, A. Yen, T.K. Hughes, and S.K. Tyring. Expression of human herpesvirus 8 (HHV-8) cellular homologue genes in classic and AIDS related Kaposi's sarcomas. Second National AIDS Malignancy Conference, Bethesda; April 6-8, 1998.
 37. Hudnall, S.D., P. Rady, A. Yen, and S.K. Tyring. Effect of hydrocortisone treatment on expression of human herpesvirus 8 (HHV-8) genes and on viral DNA replication in BCBL-1 cells. First Annual Meeting of Kaposi's Sarcoma Associated Herpesvirus and Related Agents, Santa Cruz; July 25-28, 1998.
 38. Moore TO*, Moore AY, Kuhn J, McCarty T. "Completion Lymph Node Dissection Following Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma" at the 52nd Annual Meeting of Southwestern Surgical Congress, Colorado Springs, CO, April 9-12, 2000.
 39. Moore AY. "Basic Self-Assessment Dermatopathology Course, Cases 21-25" at the American Academy of Dermatology 59th Annual Meeting, Washington, D.C., February, 2001.
 40. Moore AY, Moore TO, Maitra A, Lapinski P, Gazdar A. "Loss of Heterozygosity in 6q22-23 in Melanomas and Intradermal Nevi" at the 62rd Annual Meeting of the Society for Investigative Dermatology, Washington, D.C., May 8-11, 2001.
 41. Moore TO*, Maitra A, Lapinski P, Netto G, McCarty TM, Gazdar A, Moore AY. "Loss of Heterozygosity in 6q22-23 in Intermediate-Thickness Melanomas Reflects Lymph Node Involvement" at the 53rd Annual Southwestern Surgical Congress, Cancun, Mexico, April, 2001.
 42. Moore TO*, McCarty T, Kuhn J, Maitra A, Gazdar A, Moore AY. "Loss of Heterozygosity at 6q22-23.3 in Congenital Nevi, Acquired Nevi, and Cutaneous Melanoma After Laser Capture Microdissection" at the 55th Annual Meeting of the Society of Surgical Oncology, Denver, CO, March 14-17, 2002.
 43. Moore AY, Moore TO*, Sinkre P, Ashfaq R. "Expression of CD117 (c-kit) in Dermatofibrosarcoma Protuberans: An Immunohistochemical Study of 25 Cases" at the 63rd Annual Meeting of the Society for Investigative Dermatology, Los Angeles, CA, May 15-18, 2002.
 44. Moore TO*, Moore AY, Gazdar A. "Methylation Profiles of Tumor Suppressor Genes in Basal Cell and Squamous Cell Carcinoma," 61st Annual Meeting of the American Academy of Dermatology, San Francisco, CA, March 21-26, 2003.
 45. Moore AY*. "Oral Bexarotene and Narrowband UVB Phototherapy in the Treatment of Moderate-to-Severe Plaque Psoriasis," 61st Annual Meeting of the American Academy of Dermatology, San Francisco, CA, March 21-26, 2003.

46. Oral presentation with Stephen Tyring MD, Omar Lupi MD, and Gloria Sanclemente MD "Viral Infections" at the 65th Annual American Academy of Dermatology Meeting 2006 in Washington, DC, February 2007.
47. Oral presentation with Stephen Tyring, MD, "Should you Vaccinate your Patients for HPV and Zoster?" at the Summer Meeting of the American Academy of Dermatology, New York City, New York, August 2007.
48. Moore AY and the Tough Acne Management Evaluation (TAME) Study Group . "Evaluating Tazarotene in the Treatment of Moderate or Severe Facial Acne Vulgaris: Results from the Tough Acne Management Evaluation (TAME) Study," Summer Meeting of the American Academy of Dermatology, New York City, New York, August 2007.

* in-training

Regional Presentations

1. Oral presentation on "Cytotoxic and Growth Profiles of Natural Killer Cells from Patients with Leukemia," performed with E. Lotzova at the University of Texas System Cancer Center Summer Research Program, August, 1985.
2. Oral presentation on "Pemphigus Erythematosus" at the John M Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1993.
3. Oral presentation on "Congenital Smooth Muscle Hamartoma" at the John M Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1993.
4. Oral presentation on "Elastoderma" at the Clarence S. Livingood Lecture, Houston Dermatological Society Meeting, Galveston, Texas, April, 1994.
5. Oral presentation on "Multiple Glomus Tumors" at the Clarence S. Livingood Lecture, Houston Dermatological Society Meeting, Galveston, Texas, April, 1994.
6. Oral presentation on "Predesquamin Extends Maturation of Keratinocytes" at the Texas Dermatological Society Meeting, Austin, Texas, May, 1994.
7. Oral presentation on "Effect of Dietary Lipids on PUVA Phototoxicity in the Hairless Mouse" at the South Central Dermatologic Congress Meeting at Key West, Florida, July, 1994.
8. Oral presentation on "Elastoderma: A Clinical Mimic of Acquired Cutis Laxa" at the South Central Dermatologic Congress Meeting at Key West, Florida , July, 1994.
9. Oral presentation on "Elastoderma" at the Pacific Dermatologic Association Clinicopathologic Conference at Tuscon, AZ, October, 1994.

10. Oral presentation on "Erythema Induratum" at the Clarence S. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1995.
11. Oral presentation on "Kikuchi's Histiocytic Necrotizing Lymphadenitis" at the Clarence S. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1995.
12. Oral presentation on "Workplace Skin Cancer Screening After Pre-Screening Questionnaires" at Texas Dermatological Society Meeting, Dallas, Texas, May, 1995.
13. Oral presentation on "Erythema Induratum of Bazin as a Tuberculid" at the Southern Medical Association Meeting, Dermatology Section, Kansas City, Kansas, November, 1995.
14. Yen A, Rady P, Jones A, Orengo I, Bruce S, Wagner Jr R, Tyring SK. "Prevalence of HHV-8 in Cutaneous Neoplasms" at the Southern Society for Investigative Dermatology Meeting, New Orleans, LA, February, 1996.
15. Oral presentation on "Linear Scleroderma" at the Clarence S. Livingood Lecture, Houston Dermatological Society Meeting, Galveston, Texas, March, 1996.
16. Oral presentation on "Multiple Spitz Nevi and Nevus Sebaceous" at the Clarence S. Livingood Lecture, Houston Dermatological Society Meeting, Galveston, Texas, March, 1996.
17. Oral presentation on "Histiocytic Cytophagic Panniculitic vs. Subcutaneous T-cell Lymphoma" at the Clarence S. Livingood Lecture, Houston Dermatological Society Meeting, Galveston, Texas, March, 1996.
18. Yen A, Rady P, Jones A, Orengo I, Bruce S, Wagner R Jr., Tyring SK. "Prevalence of HHV-8 in Cutaneous Neoplasms" at the 1996 Annual McLaughlin Fellowship Colloquium, Galveston, Texas, March, 1996.
19. Oral presentation on "Prevalence of Human Herpesvirus 8 DNA in Kaposi's Sarcoma, Carcinomas, and Post-transplant Squamous Lesions" at the Texas Dermatological Society, San Antonio, Texas, May, 1996.
20. Oral presentation on "Histology of Cutaneous Polyarteritis Nodosa" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
21. Oral presentation on "Histology of Adult-Onset Urticaria Pigmentosa" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
22. Oral presentation on "Histology of Cutaneous Mycobacterium Chelonae Infection" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.

23. Oral presentation on "Histology of Acquired Perforating Folliculitis" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
24. Oral presentation on "Histology of Incontinentia Pigmenti" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
25. Oral presentation on "Histology of Erythema Dyschronicum Perstans" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
26. Oral presentation on "Histology of Metastatic Adenocarcinoma to the Skin" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
27. Oral presentation on "Histology of Lichen Planus" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
28. Oral presentation on "Histology of High-grade Diffuse Large-Cell Lymphoma Presenting with Lepromatous Leprosy" at the John M. Knox Memorial Lecture, Houston Dermatological Society Meeting, Galveston, Texas, September, 1996.
29. Oral presentation on "Histology of Linear IgA Bullous Disease" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.
30. Oral presentation on "Histology of Morphea and Lichen Sclerosus et Atrophicus" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.
31. Oral presentation on "Histology of Hypopigmented Mycosis Fungoides" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.
32. Oral presentation on "Histology of Steatocystoma Multiplex" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.
33. Oral presentation on "Histology of Progressive Facial Hemiatrophy with Associated Orbital Pseudotumor" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.
34. Oral presentation on "Histology of Cowden's Syndrome and Mucosal Involvement" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.
35. Oral presentation on "Histology of Chloracne Secondary to Petroleum Products" at the Clarence C. Livingood Lecture Case Presentations, Houston Dermatological Society Meeting, Galveston, Texas, April, 1997.

Meeting, Galveston, Texas, April, 1997.

36. Oral presentation on “The Need for Completion Lymph Node Dissection Following Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma” at the North Texas Chapter, American College of Surgeons Meeting, Dallas, Texas, February, 1999.
37. Moore TO, Maitra A, Lapinski P, Netto G, McCarty T, Gazdar A, Moore AY. “Loss of Heterozygosity in 6q22-23 in Intermediate-Thickness Melanomas Reflects Lymph Node Involvement” at the North Texas Chapter, American College of Surgeons Meeting, Dallas, Texas, February, 2001.
38. Moore TO, McCarty T, Kuhn J, Maitra A, Gazdar A, Moore AY. “Loss of Heterozygosity at 6q22-23.3 in Congenital Nevi, Acquired Nevi, and Cutaneous Melanoma after Laser Capture Microdissection” at the North Texas Chapter, American College of Surgeons Meeting, Dallas, Texas, February, 2002.
39. Moore, TO*, Moore AY, Makarla P, Gazdar AF. “Methylation Profiles of Tumor Suppressor Genes in Basal and Squamous Cell Carcinoma” at the 42nd Annual Meeting of the North Texas Chapter of the American College of Surgeons, Dallas, TX, February 21, 2003.